Esperion Therapeutics, Inc. (ESPR)
Jul 13, 2026 - ESPR was delisted
3.180
-0.010 (-0.31%)
Inactive · Last trade price on Jul 10, 2026
Esperion Therapeutics Employees
Esperion Therapeutics had 294 employees as of December 31, 2025. The number of employees decreased by 10 or -3.29% compared to the previous year.
Employees
294
Change (1Y)
-10
Growth (1Y)
-3.29%
Revenue / Employee
$1,422,599
Profits / Employee
-$25,248
Market Cap
819.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 294 | -10 | -3.29% |
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
ESPR News
- 4 weeks ago - Esperion Therapeutics Transcript: EGM 2026 - Transcripts
- 7 weeks ago - Esperion Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Esperion Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Esperion Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Esperion Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 - GlobeNewsWire
- 3 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - GlobeNewsWire